Professor Marcelin: I think this is a good idea because we know the nucleoside and nucleotide analogs are sublimitation and also you got your own limitations.

Professor Marcelin: Currently we have the reserves of the phase II studies for some protease inhibitor especially for two protease inhibitors telaprevir and boceprevir.